Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy

Boris Gorovits(Pfizer (United States)), Bonnie Wu(Janssen (United States)), Mike Havert(Bluebird Bio (United States)), Travis Harrison(Precision for Medicine (United States)), Sylvia Janetzki(Yale University), Yolanda D. Mahnke, Mitra Azadeh(Alkermes (United States)), Michele Fiscella(Regenxbio (United States)), George Buchlis(University of Pennsylvania), Andrew J. McDermott(LabCorp (United States)), Mark Milton(Novartis (United States)), Christian Vettermann(Eureka Therapeutics (United States)), Robert Nelson, Brian Long(BioMarin (United States)), Vibha Jawa(EpiVax (United States))
The AAPS Journal
April 26, 2023
10.1208/s12248-023-00814-5
Cited by 41

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
|Clinical Cancer Research|2011|109
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53